L. Dirix

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

Marcus Schmidt, M. E. Scheulen, Christian Dittrich et al. · Annals of Oncology · 2009 · 130 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +8

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

Eric Van Cutsem, David Cunningham, W.W. ten Bokkel Huinink et al. · European Journal of Cancer · 1999 · 109 citations · Full text

Health Sciences, Medicine, Pharmacology +8

Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

L. Dirix, István Takács, Petros Nikolinakos et al. · Cancer Research · 2016 · 108 citations

Breast Oncology, Immunology, Programmed Death-1 Receptor +16

Intraoperative sentinel node identification with Technetium-99m-labeled nanocolloid in patients with cancer of the uterine cervix: A feasibility study

Peter A. van Dam, Jan Hauspy, T. Vanderheyden et al. · International Journal of Gynecological Cancer · 2003 · 80 citations

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

Sara A. Hurvitz, L. Dirix, Judit Kocsis et al. · European Journal of Cancer · 2011 · 54 citations

Oral Trastuzumab Emtansine, Oncology, Breast Oncology +8